Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage

Artif Cells Blood Substit Immobil Biotechnol. 2011 Apr;39(2):59-68. doi: 10.3109/10731199.2010.501755. Epub 2010 Jul 20.

Abstract

Exsanguinating hemorrhage and unavailability of blood are major problems in pre-hospital trauma care. We investigated if combining rFVIIa with HBOC-201 reduces blood loss and improves physiologic parameters compared to HBOC alone. Swine underwent liver injury and were resuscitated with HBOC-201 alone or HBOC+90, 180 or 360 μg/kg rFVIIa before hospital arrival at 240 min; animals survived to 72 hours. Blood loss was reduced; MAP, CI, transcutaneous oxygen saturation, and 72-hour survival improved in the 90 and 180 μg/kg rFVIIa groups. Lactate was cleared faster in the HBOC+rFVIIa 90 μg/kg group. Verification in a large, well-powered study is indicated.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Blood Gas Analysis / methods
  • Blood Pressure / physiology
  • Blood Substitutes / administration & dosage*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Factor VIIa / administration & dosage*
  • Female
  • Fluid Therapy / methods*
  • Heart Rate / physiology
  • Hemoglobins / administration & dosage*
  • Hemorrhage / mortality
  • Hemorrhage / therapy*
  • Lactic Acid / analysis
  • Lactic Acid / blood
  • Liver / injuries
  • Male
  • Recombinant Proteins / administration & dosage
  • Resuscitation
  • Survival Rate
  • Swine

Substances

  • Blood Substitutes
  • Hemoglobins
  • Recombinant Proteins
  • HBOC 201
  • Lactic Acid
  • recombinant FVIIa
  • Factor VIIa